Sesen Bio Inc. (SESN)’s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX)

Both Sesen Bio Inc. (NASDAQ:SESN) and BioLineRx Ltd. (NASDAQ:BLRX) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sesen Bio Inc. N/A 0.00 33.48M -0.67 0.00
BioLineRx Ltd. N/A 0.00 24.67M -0.23 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Sesen Bio Inc. and BioLineRx Ltd.


Table 2 demonstrates the return on assets, net margins and return on equity of Sesen Bio Inc. and BioLineRx Ltd.

Net Margins Return on Equity Return on Assets
Sesen Bio Inc. 0.00% -85.7% -33.6%
BioLineRx Ltd. 0.00% 0% 0%

Institutional and Insider Ownership

Sesen Bio Inc. and BioLineRx Ltd. has shares owned by institutional investors as follows: 49.9% and 36.06%. Insiders owned 6.35% of Sesen Bio Inc. shares. Insiders Comparatively, owned 4.39% of BioLineRx Ltd. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sesen Bio Inc. -8.67% 2.6% -30.4% -37.05% 132.76% 94.82%
BioLineRx Ltd. -2.75% -10.11% -26.06% -29.64% -40.1% -39%

For the past year Sesen Bio Inc. has 94.82% stronger performance while BioLineRx Ltd. has -39% weaker performance.


BioLineRx Ltd. beats on 4 of the 6 factors Sesen Bio Inc.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.